A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety andTolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participa
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
December 19, 2019
End Date
October 5, 2023
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
December 19, 2019
End Date
October 5, 2023